Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma — ERICA

Renal Cell Carcinoma, Metastatic Clinical Trial

Official title:
ERICA: Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

Status Terminated

Clinical Trial Summary

The objective of the trial is to determine the clinical efficacy of ESK981 in combination with nivolumab therapy in patients with metastatic renal cell carcinoma (RCC).

Clinical Trial Description

The study was terminated early due to changes in the RCC treatment landscape which limited the patient population. Due to this early termination no subjects were enrolled into Cohort B. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03562507
Study type	Interventional
Source	University of Michigan Rogel Cancer Center
Contact
Status	Terminated
Phase	Phase 2
Start date	April 11, 2019
Completion date	October 18, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03991130` - High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma	Phase 2
Recruiting	`NCT03013946` - Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy	Phase 3
Active, not recruiting	`NCT02974738` - A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)	Phase 1
Completed	`NCT02432846` - Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)	Phase 2